Past medical history of tumors other than meningioma is a negative prognostic factor for tumor recurrence in meningiomas WHO grade I.
Meningioma
Prognostic factor
TERT promoter status
Unrelated tumor disease
WHO grade I
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
31
12
2020
accepted:
19
02
2021
pubmed:
7
3
2021
medline:
25
11
2021
entrez:
6
3
2021
Statut:
ppublish
Résumé
Prognostic markers for meningioma recurrence are needed to guide patient management. Apart from rare hereditary syndromes, the impact of a previous unrelated tumor disease on meningioma recurrence has not been described before. We retrospectively searched our database for patients with meningioma WHO grade I and complete resection provided between 2002 and 2016. Demographical, clinical, pathological, and outcome data were recorded. The following covariates were included in the statistical model: age, sex, clinical history of unrelated tumor disease, and localization (skull base vs. convexity). Particular interest was paid to the patients' past medical history. The study endpoint was date of tumor recurrence on imaging. Prognostic factors were obtained from multivariate proportional hazards models. Out of 976 meningioma patients diagnosed with a meningioma WHO grade I, 416 patients fulfilled our inclusion criteria. We encountered 305 women and 111 men with a median age of 57 years (range: 21-89 years). Forty-six patients suffered from a tumor other than meningioma, and no TERT mutation was detected in these patients. There were no differences between patients with and without a positive oncological history in terms of age, tumor localization, or mitotic cell count. Clinical history of prior tumors other than meningioma showed the strongest association with meningioma recurrence (p = 0.004, HR = 3.113, CI = 1.431-6.771) both on uni- and multivariate analysis. Past medical history of tumors other than meningioma might be associated with an increased risk of meningioma recurrence. A detailed pre-surgical history might help to identify patients at risk for early recurrence.
Sections du résumé
BACKGROUND
Prognostic markers for meningioma recurrence are needed to guide patient management. Apart from rare hereditary syndromes, the impact of a previous unrelated tumor disease on meningioma recurrence has not been described before.
METHODS
We retrospectively searched our database for patients with meningioma WHO grade I and complete resection provided between 2002 and 2016. Demographical, clinical, pathological, and outcome data were recorded. The following covariates were included in the statistical model: age, sex, clinical history of unrelated tumor disease, and localization (skull base vs. convexity). Particular interest was paid to the patients' past medical history. The study endpoint was date of tumor recurrence on imaging. Prognostic factors were obtained from multivariate proportional hazards models.
RESULTS
Out of 976 meningioma patients diagnosed with a meningioma WHO grade I, 416 patients fulfilled our inclusion criteria. We encountered 305 women and 111 men with a median age of 57 years (range: 21-89 years). Forty-six patients suffered from a tumor other than meningioma, and no TERT mutation was detected in these patients. There were no differences between patients with and without a positive oncological history in terms of age, tumor localization, or mitotic cell count. Clinical history of prior tumors other than meningioma showed the strongest association with meningioma recurrence (p = 0.004, HR = 3.113, CI = 1.431-6.771) both on uni- and multivariate analysis.
CONCLUSION
Past medical history of tumors other than meningioma might be associated with an increased risk of meningioma recurrence. A detailed pre-surgical history might help to identify patients at risk for early recurrence.
Identifiants
pubmed: 33674888
doi: 10.1007/s00701-021-04780-9
pii: 10.1007/s00701-021-04780-9
pmc: PMC8437882
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2853-2859Informations de copyright
© 2021. The Author(s).
Références
Neuro Oncol. 2012 Jul;14(7):902-9
pubmed: 22561798
J Neurosurg. 2014 Mar;120(3):655-61
pubmed: 24313608
J Neurosurg. 2010 Nov;113(5):1115-21
pubmed: 20433279
Am J Surg Pathol. 1997 Dec;21(12):1455-65
pubmed: 9414189
Cancer Causes Control. 2014 Jun;25(6):659-68
pubmed: 24682745
Int J Cancer. 2006 Sep 1;119(5):1152-7
pubmed: 16570277
Lancet Oncol. 2017 May;18(5):682-694
pubmed: 28314689
Anticancer Res. 2018 May;38(5):2819-2822
pubmed: 29715104
Skull Base. 2007 May;17(3):157-71
pubmed: 17973029
Front Oncol. 2020 Aug 28;10:1522
pubmed: 32983999
Neurosurgery. 2020 Dec 15;88(1):140-146
pubmed: 32827256
Ann Oncol. 2012 Apr;23(4):843-52
pubmed: 21890910
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
J Natl Cancer Inst. 2015 Dec 13;108(5):
pubmed: 26668184
J Neurosurg. 2020 Jan 3;:1-7
pubmed: 31899874
PLoS One. 2017 Jul 14;12(7):e0181089
pubmed: 28708856
J Natl Cancer Inst. 2008 Feb 20;100(4):270-6
pubmed: 18270339
J Neurosurg. 2011 Dec;115(6):1072-7
pubmed: 21780859
Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95
pubmed: 16331155
J Neurosurg. 2016 Sep;125(3):551-60
pubmed: 26824369
J Neurosurg. 2012 Jul;117(1):121-8
pubmed: 22559847
Oncotarget. 2017 Jan 10;8(2):2284-2292
pubmed: 27903988
Neuro Oncol. 2011 Dec;13(12):1331-8
pubmed: 21896554
J Neurooncol. 2018 Sep;139(3):671-678
pubmed: 29808339
Am J Epidemiol. 2006 Mar 15;163(6):521-7
pubmed: 16421240
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Neurosurgery. 1997 Nov;41(5):1152-9
pubmed: 9361071
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931